Home › Results of Phase 2 Study of Mercks Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
 

Keywords :   


Results of Phase 2 Study of Mercks Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe

2016-06-20 18:30:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Pivotal Phase 3 Studies Ongoing in Treatment of Serious Bacterial Infections KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the companys investigational beta-lactamase inhibitor, in combination with imipenem/cilastatin (an approved carbapenem antibiotic), in patients with complicated urinary tract infections, met its primary endpoint. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558orRobert Consalvo, (908) 295-0928orInvestor:Teri Loxam, (908) 740-1986orAmy Klug, (908) 740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: results study presented combination

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
05.11Tropical Storm Rafael Wind Speed Probabilities Number 6
05.11Tropical Storm Rafael Public Advisory Number 6
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 6
05.11Why colouring clothes has a big environmental impact
05.11Atlantic Tropical Weather Outlook
More »